Assessment of the Efficacy and Safety of (HCQ) as a Prophylaxis for COVID19 for Health Professionals (COVID_2Pro)

Abderrahmane Mami Hospital

Status and phase

Withdrawn

Phase 3

Conditions

Sars-CoV2

Hydroxychloroquine

Healthcare Worker

COVID19

Prophylaxis

Treatments

Drug: Placebo oral tablet

Drug: Hydroxychloroquine (HCQ)

Study type

Interventional

Funder types

Other

NETWORK

Industry

Identifiers

NCT04349228

ECC2020-03

Details and patient eligibility

About

Assessment of the Efficacy and Safety of Hydroxychloroquine (HCQ) Administered as a Prophylaxis for Health Professionals Exposed to COVID19 and Working in Medical Intensive Care Units, in Tunisia. Multicentric, Randomized Comparative Study

Full description

Interventional, Multicentric, Randomized Controlled Study in Two Parallel Groups of 530 Healthcare Professionals working in the Intensive Care Unit Exposed to Risk of COVID19 Infection Taking Hydroxychloroquine (HCQ) (200 mg/day) VS Placebo

Sex

All

Ages

18 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Diagnosis of COVID-19 (-)
Works in a medical intensive care unit exposed to COVID-19 infection
18 years old < age < 65 years old
Having given written consent for their participation in the study.

Exclusion criteria

Diagnosis of COVID-19+
Retinopathies,
Hydroxychloroquine or other prophylactic treatments for VIDOC19 within one month prior to inclusion and throughout the study.
Hypersensitivity to chloroquine or hydroxychloroquine or 4-aminoquinolines or any of the other components of this drug,
Contraindication to prophylactic use of chloroquine, e.g. liver failure, known epilepsy, creatinine clearance < 30 ml/min.
Inability to be monitored during the trial period
Pregnancy and breastfeeding
Psoriasis